Eli Lilly has registered a Phase III clinical trial (NCT07035093) on ClinicalTrials.gov to evaluate the efficacy and safety of retatrutide, a GLP-1/GIP/glucagon triple agonist, in patients with obesity or overweight and chronic low back pain (CLBP). The study aims to enrol 586 participants with an estimated 80-week follow-up period, with primary completion targeted for September 2027.

The randomized, double-blind, placebo-controlled study will investigate the efficacy and safety of retatrutide once weekly as a potential treatment for CLBP, a condition often linked to obesity.

Retatrutide, the first-in-class GLP-1/GIP/glucagon triple agonist, is already under investigation in multiple Phase III trials for weight loss, type 2 diabetes (T2D) and chronic kidney disease (CKD), with this study expanding its potential therapeutic applications.

Source:
https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247527728&idx=2&sn=a118fcfde623852da5e5085674db2eae